Heather Mefford, MD, PhD
Faculty, Department of Cell & Molecular Biology
Heather Mefford, MD, PhD, is a faculty member in the Department of Cell & Molecular Biology at St. Jude.
Stories by Heather Mefford
A new cancer therapy DAWNs
Read how this pre-clinical research fast-tracked a clinical trial for a diabolical pediatric brain tumor.
The St. Jude Affiliate Clinic at Mercy Children’s Hospital celebrates a decade of life-saving care
Read how the Mercy hospital in Springfield, Missouri, has grown since becoming a St. Jude affiliate clinic.
Rare childhood disorders widen window on diseases of aging
Read how extremely rare genetic childhood diseases offer clues about understanding neurodegenerative disorders common with aging.
How do you tackle a rare cancer?
The rarest pediatric cancers are poorly understood, and more information can inform progress on disorders that plague children.
Adult pediatric cancer survivor represents St. Jude on Capitol Hill
Medical student and pediatric cancer survivor goes to Washington D.C., to advocate for children’s health.
This proposed solution to a long-standing cellular mystery comes with a visual aid
It may look like some sort of strange modern art – but it’s a simple machine describing a very complicated, and mysterious, process.
PeCanPIE offers powerful tools for discovering inherited cancer genes
Powerful cancer data portal gets an upgrade to identify the genetic culprit for inherited cancer and possibly other genetic diseases.
Psychology’s 10th anniversary: Department chair remembers modest beginnings, remarkable growth
Learn how psychologists use their clinical and research expertise to help children with cancer and other life-threatening diseases.
The St. Jude School Program’s new principal has learned a thing or two
It’s difficult to do school when you’re fighting cancer, but this new approach to learning may make learning fun again for cancer patients.
Pediatric immunotherapy: How two immunologists are paving the way for improved treatments
Two friends and research colleagues are looking at different stages of the immune response to pave the way for enhanced cancer treatments.